Summary
14.47 0.58(4.14%)09/05/2024
Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals Inc (DAWN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 4.40 | 5.74 | 9.92 | 10.72 | -13.28 | 2.73 | 0.00 | 3,502.73 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 14.47 | |
| Open | 14.04 | |
| High | 14.57 | |
| Low | 13.86 | |
| Volume | 728,435 | |
| Change | 0.61 | |
| Change % | 4.40 | |
| Avg Volume (20 Days) | 692,243 | |
| Volume/Avg Volume (20 Days) Ratio | 1.05 | |
| 52 Week Range | 9.67 - 18.07 | |
| Price vs 52 Week High | -19.95% | |
| Price vs 52 Week Low | 49.59% | |
| Range | 3.03 | |
| Gap Up/Down | 0.13 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,219 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 35.00 | |
| Book Value | 4.8070 | |
| Earnings Per Share | -8.8530 | |
| EPS Estimate Current Quarter | -0.2800 | |
| EPS Estimate Next Quarter | -0.3200 | |
| EPS Estimate Current Year | -3.3600 | |
| EPS Estimate Next Year | -1.7100 | |
| Diluted EPS (TTM) | -8.8530 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.6179 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 61,928,900 | |
| Shares Float | 18,919,291 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 33.11 | |
| Institutions (%) | 47.53 | |
08/14 11:46 EST - investorplace.com
Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
When volatility strikes the stock market as it sets new highs, investors get nervous. Wild swings in price can often signal a market top.
Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
When volatility strikes the stock market as it sets new highs, investors get nervous. Wild swings in price can often signal a market top.
07/30 09:40 EST - zacks.com
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.61 per share a year ago.
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.61 per share a year ago.
07/30 07:30 EST - globenewswire.com
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
Achieved $8.2 million in OJEMDA TM (tovorafenib) net product revenues in initial 2 months of launch
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
Achieved $8.2 million in OJEMDA TM (tovorafenib) net product revenues in initial 2 months of launch
07/30 07:00 EST - globenewswire.com
Day One Announces Oversubscribed $175.0 Million Private Placement
BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $175.0 million, before deducting placement agent fees and other expenses.
Day One Announces Oversubscribed $175.0 Million Private Placement
BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $175.0 million, before deducting placement agent fees and other expenses.
07/25 00:58 EST - globenewswire.com
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Day One Biopharmaceuticals (Nasdaq: DAWN) (Day One), announced today a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma (pLGG), the most common form of childhood brain cancer, i and any future indications developed by Day One.
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Day One Biopharmaceuticals (Nasdaq: DAWN) (Day One), announced today a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma (pLGG), the most common form of childhood brain cancer, i and any future indications developed by Day One.
06/19 11:30 EST - zacks.com
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
06/18 08:30 EST - globenewswire.com
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024
05/30 08:30 EST - globenewswire.com
Day One Announces Sale of Priority Review Voucher for $108 Million
BRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it sold its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. The Company was awarded the PRV following the U.S. Food and Drug Administration (FDA) accelerated approval of OJEMDA™ (tovorafenib).
Day One Announces Sale of Priority Review Voucher for $108 Million
BRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it sold its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. The Company was awarded the PRV following the U.S. Food and Drug Administration (FDA) accelerated approval of OJEMDA™ (tovorafenib).
05/06 16:30 EST - globenewswire.com
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
04/23 15:56 EST - globenewswire.com
Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Co
Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Co
02/26 16:30 EST - globenewswire.com
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024
02/01 10:07 EST - seekingalpha.com
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Day One Biopharmaceuticals is a leader in pediatric oncology, with a focus on addressing the unmet needs of pediatric cancer patients. The company has a strong financial position, with enough cash to fund operations through 2026, and is progressing through clinical trials with promising results. Day One's lead product candidate, tovorafenib, has the potential to redefine the standard of care for pediatric low-grade glioma, pending regulatory approval.
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Day One Biopharmaceuticals is a leader in pediatric oncology, with a focus on addressing the unmet needs of pediatric cancer patients. The company has a strong financial position, with enough cash to fund operations through 2026, and is progressing through clinical trials with promising results. Day One's lead product candidate, tovorafenib, has the potential to redefine the standard of care for pediatric low-grade glioma, pending regulatory approval.
12/19 08:00 EST - globenewswire.com
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time.
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time.
11/17 07:00 EST - globenewswire.com
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting
11/06 16:30 EST - globenewswire.com
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
NDA for tovorafenib in relapsed or progressive pLGG accepted for FDA priority review PDUFA target action date of April 30, 2024 BRISBANE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its third quarter 2023 financial results and highlighted recent corporate achievements.
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
NDA for tovorafenib in relapsed or progressive pLGG accepted for FDA priority review PDUFA target action date of April 30, 2024 BRISBANE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its third quarter 2023 financial results and highlighted recent corporate achievements.
10/30 08:00 EST - globenewswire.com
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (pLGG).
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (pLGG).
09/15 15:21 EST - seekingalpha.com
Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch
Day One Biopharmaceuticals, Inc. is awaiting an FDA filing decision on its lead drug tovorafenib for the treatment of pediatric low grade glioma in mid-November of 2023. The company is also running a phase 3 study to evaluate tovorafenib as a first-line treatment for pLGG. Tovorafenib is being explored alone and in combination with another drug in ongoing phase 1b/2 studies for MAPK pathway mutated solid tumors.
Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch
Day One Biopharmaceuticals, Inc. is awaiting an FDA filing decision on its lead drug tovorafenib for the treatment of pediatric low grade glioma in mid-November of 2023. The company is also running a phase 3 study to evaluate tovorafenib as a first-line treatment for pLGG. Tovorafenib is being explored alone and in combination with another drug in ongoing phase 1b/2 studies for MAPK pathway mutated solid tumors.
09/11 21:02 EST - globenewswire.com
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA filing decision expected by mid-November BRISBANE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the recently completed submission of the rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (pLGG).
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA filing decision expected by mid-November BRISBANE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the recently completed submission of the rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (pLGG).
08/07 16:30 EST - globenewswire.com
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma (RANO-HGG) evaluable patients presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma (RANO-HGG) evaluable patients presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting